Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.

Oncotarget · 2017 · PMC5652683 · PMID 29100289

Europe PMC DOI

hedged sentences

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp<0.0001actually significant

This difference was highly significant with p<0.0001.

also in 132,142 other papers

did not reach statistical significancep=0.088so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

The disease control rate showed a trend towards a better outcome in chemosensitivity-directed combination therapy (32.8% vs 23.0%); however, this difference did not reach statistical significance (p=0.088).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.